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TURUN YLIOPISTO  
Lääketieteellinen tiedekunta 
 
ROOPE RAITANEN: PET-measurable reduction in innate immune cell 
activation in PPMS brain after rituximab treatment 




A 48-year-old woman with primary progressive multiple sclerosis (PPMS) was started 
on rituximab shortly after diagnosis. She underwent serial PET-imaging at an 18-month 
interval using [11C]PK11195, a first generation 18-kDa translocator protein ligand 
targeting activated brain microglia and macrophages, before and after rituximab. I 
participated in the study as an assistant, and I handled the first processing of the MRI-
images. The case report is meant to be published in Multiple sclerosis journal in 2021. 
 
Rituximab is a monoclonal antibody, that identifies CD20-molecule on the surface of B-
lymphocytes. Rituximab causes apoptosis in all the cells it binds to. B-cell activation is 
linked to MS pathogenesis and it has been shown in studies that decreased B-cell levels 
correlate with better outcome clinically and radiologically in RRMS- and young PPMS-
patients. Rituximab does not have an official indication for treating MS, but later 
developed Ocrelizumab works very similarly to it and got an indication in 2018 in the 
European markets. 
 
The patient remained clinically stable during a five-year follow-up, and a decrease in 
radioligand binding was noted in brain areas relevant to progressive MS pathology, such 
as perilesional white matter area and thalamus. The finding implicates that efficient and 
early B-cell therapy may lead to reduced microglial activation in PPMS, which may 
slow down later disease progression.  
 
The case report opens new vistas for designing future therapeutic studies that use the 
evaluation of microglial activation as an imaging outcome measure in MS. The study is 
also in line with previous studies that have shown the predictive value of TSPO-PET 
imaging compared to conventional MRI. 
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A 48-year-old woman with primary progressive multiple sclerosis (PPMS) was started on rituximab 
shortly after diagnosis. She underwent serial PET-imaging at an 18-month interval using 
[11C]PK11195, a first generation 18-kDa translocator protein ligand targeting activated brain 
microglia and macrophages, before and after rituximab. She remained clinically stable during a 
five-year follow-up, and a decrease in radioligand binding was noted in brain areas relevant to 
progressive MS pathology, such as perilesional white matter area and thalamus. The finding 
implicates that efficient and early B-cell therapy may lead to reduced microglial activation in 
PPMS, which may slow down later disease progression.   
 
Introduction 
Primary progressive multiple sclerosis (PPMS) has only limited treatment options and a relatively 
poor prognosis.1 Unlike in relapsing-remitting MS (RRMS), where lymphocytes enter the CNS from 
the periphery to form focal inflammatory lesions, a process readily preventable by effective immune 
modulating treatments, the pathology in PPMS is mainly contained within the CNS.2 Diffuse innate 
immune cell activation particularly in the normal appearing white matter (NAWM), in the thalamus 
and at the rim of chronic lesions is a characteristic pathological feature of PPMS, which is not 
detectable by conventional MRI.3 The innate immune cell activation is co-localized with signs of 
neural damage and is thus considered to have a central role in promoting MS progression.3 
The present DMTs have proven to be of limited value in treatment of progressive MS. Ocrelizumab 
is the first and currently the only approved therapy for PPMS, and previously another B-cell therapy, 
rituximab, demonstrated promising therapeutic effect in a Phase II PPMS study.4 B-cells have well-
known roles in antigen presentation and in cytokine and antibody production, but their precise role in 
MS immunopathology remains somewhat unclear. Particularly in progressive disease, where CNS-
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contained diffuse inflammation and neurodegeneration have a presumably important 
pathophysiological role, the mechanism of action of anti-B-cell antibodies has remained elusive, as 
monoclonal antibodies generally have low blood-brain-barrier (BBB) penetration.5  
 
Positron emission tomography (PET) using radioligands binding to the 18-kDa translocator protein 
(TSPO) molecule can be used to obtain information about the brain innate immune system activation 
in vivo.6 Studies of secondary progressive MS (SPMS) have demonstrated an increase in TSPO-
radioligand binding in brain areas relevant to progressive MS pathology, compared to RRMS patients 
and age-matched healthy controls.7 In PPMS such studies are still lacking, but in this PPMS case 
report we describe a situation, where early initiation of rituximab let to reduction in TSPO-PET-
measurable innate immune cell activation, and stabilization of the clinical disease progression.  
 
Case Report 
This individual was diagnosed with PPMS in May 2016 when she was 48 years old. She had had 
some walking difficulties since the beginning of 2015, but new symptoms emerged, including 
numbness and loss of sensory function in the right lower trunk and leg in December 2015, in addition 
to dizziness and cognitive impairment, and these led to suspicion of MS. MRI examination 
demonstrated large demyelinating lesions in the entire brain and thoracic and cervical spine. 
Cerebrospinal fluid (CSF) examination revealed elevated immunoglobulin G (IgG) index and 
oligoclonal bands. At the time ocrelizumab had not yet been approved for PPMS and off-label use of 
rituximab was the chosen DMT. The first rituximab infusion (500mg) was given in June 2016, and 
the treatment was continued first every 6 months and later with 9-month interval with no adverse 
effects.  
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TSPO-PET imaging using the [11C]PK11195 radioligand was performed before the administration of 
the first rituximab infusion and again after 18 months of treatment. Conventional MRI was performed 
at both time points. Microglial activation was evaluated as specific binding of [11C]PK11195 using 
distribution volume ratio (DVR) in the NAWM, cortical grey matter, thalamus, T1 lesion, T2 lesion 
and in the T1 perilesional area extending 3 mm into the NAWM from the lesion edge. For the 
estimation of the [11C]PK11195 DVR, the time–activity curve corresponding to a reference region 
devoid of specific TSPO-binding was acquired for both PET sessions using a supervised cluster 
algorithm with four predefined kinetic tissue classes (SuperPK software).8 The reference tissue–input 
Logan method with a time interval from 20 to 60 min, was applied to the regional time–activity curves 
using the supervised cluster algorithm reference input. Imaging data from a group of 18 age-matched 
healthy individuals obtained in a similar way, was used for comparison.9 
At baseline, our patient had higher DVR in the NAWM and thalamus compared to healthy control 
mean DVR in these areas (Table 1). After rituximab treatment, a decrease in [11C]PK11195 binding 
was observed in T1 and T2 lesions, in thalamus and in the perilesional NAWM (Table 1). No 
noticeable change in MRI T1 or T2 lesion burden was observed during the 18-month follow-up (data 
not shown). The sensory loss improved during the 18-month follow-up, and this led to a decrease in 
the Expanded Disability Status Scale (EDSS) score from 3.5 to 3.0. The patient continued on 
rituximab treatment, and at her most recent annual appointment in February 2021, her EDSS score 
was 3.0 with no noticeable change in her MRI lesion burden. 
Our case report demonstrates a decrease in TSPO-radioligand binding (reflecting reduced microglial 




The treatment result described in this paper suggests that at least in certain PPMS patients, anti-B-
cell therapy may be helpful in reducing microglial activation in brain areas most relevant for MS 
pathology. Importantly, in our patient, this phenomenon was associated with stabilization of the 
clinical worsening. Here, rituximab treatment was initiated within a month of PPMS diagnosis, and 
this might have been helpful in obtaining good control of the disease. The finding of reduced 
microglial activation after treatment with highly effective anti-inflammatory therapy is in line with 
previous studies, where other DMTs such as natalizumab and fingolimod have led to decreased 
microglial activity.10-12  
Activated microglial cells are considered harmful, and have been shown to predict later disease 
progression independent of relapses.9 Furthermore, increased iron uptake at lesion edge (reflecting 
microglial activity) was associated with more rapid clinical disease progression.13 Despite the 
promising outcome presented in our patient case, the results cannot be directly extended to larger 
groups, where heterogenous underlying pathologies likely exist. Our case however gives a promising 
signal that anti-B-cell therapies might be effective in reducing the smoldering inflammation contained 
behind the BBB. It is unlikely that rituximab, being a large monoclonal antibody, would enter the 
CNS but rather, the positive treatment effect on the innate immune cell activation within the CNS 
likely comes as a secondary effect from the effective reduction of the inflammatory MS-related 
activity in the periphery. The key to success in treatment of PPMS, like RRMS, seems to be early 
initiation of effective therapy. In the future, treatments targeting directly the CNS innate immune cells 
can hopefully be combined to the present effective anti-inflammatory therapies for the maximal 
benefit of the patients. 
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Table 1. Evaluation of innate immune cell activation in various brain regions of interest performed 
using PET imaging and the TSPO-binding [11C]PK11195 radioligand. 
 
 
DVR at baseline DVR at 18 months  DVR of HC* (mean±SD) 
Thalamus 1,49 1,42 1,28 (± 0,06) 
NAWM 1,26 1,26 1,19 (± 0,04) 
Cortical GM 1,15 1,19 1,23 (± 0,04) 
T1 lesion rim 0-3mm 1,29 1,25  N/A 
T1 lesion 1,24 1,23  N/A 
T2 lesion 1,26 1,23 N/A 
*n=18. Abbreviations: DVR = distribution volume ratio; HC = healthy control; NAWM = normal appearing 






Image 1. Visual demonstration of innate immune cell activation in PPMS brain. Axial view of 
3DT1 MRIs (left) and respective DVR images (right) at baseline (top row) and after 18 months of 
rituximab-treatment (bottom row). White arrows point at two representative individual lesions, 
whose high innate immune cell activation (high DVR) are visualized as 3D surface plots in the top 
PET image. Post-treatment image demonstrates a decrease in [11C]PK11195 -radioligand binding 
in these lesions after treatment. The colour bar of the PET images shows the dynamic range of DVR 
in the images. PPMS = primary progressive MS, DVR = distribution volume ratio 
